HeadSense closes financing for non-invasive intracranial pressure monitor

NewsGuard 100/100 Score

HeadSense, an early stage company developing a non-invasive neurological monitor focused initially on an intracranial pressure (ICP) application, today announced it closed financing led by Pontifax, a leading Israeli VC; GE Ventures of Menlo Park, California, USA; Everett Partners, an investment group based out of Akron, Ohio, USA; and JuMaJo, an investment group from Hamburg, Germany.

“Disruptive digital and mobile health innovation, like HeadSense, is crucial to improving the quality and affordability of healthcare. We are excited to help HeadSense as it brings its technology to market.”

HeadSense will use the investment to continue to expand its revolutionary work in bringing to market its non-invasive ICP monitor. HeadSense's device includes an earbuds-like disposable unit that is placed in the patient's ears. The device generates an acoustic signal that is circulated through the head and then is picked up in the other ear using an acoustic sensor. The data generated from the signal can then be analyzed in real-time from a tablet or smartphone.

Guy Weinberg, CEO of HeadSense, said, "Intracranial pressure is an important parameter for the diagnosis and monitoring of patients suffering from head trauma, strokes and other conditions. The current gold-standard is expensive, invasive and requires a skilled neurosurgeon. With this new distributive technology we are offering a non-invasive, accurate, continuous and cost-effective alternative that will improve patient care by allowing more patients to be monitored with reduced costs."

Noah Lewis, managing director, GE Ventures, Healthcare said, "Disruptive digital and mobile health innovation, like HeadSense, is crucial to improving the quality and affordability of healthcare. We are excited to help HeadSense as it brings its technology to market."

Financial terms of the transaction were not disclosed.

Source:

HeadSense Medical Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI technologies can accurately identify cases of healthcare-associated infections